• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Life Science Virtual Investor Forum Agenda Announced for September 18th

    9/16/25 11:57:15 AM ET
    $DRMA
    $INM
    $PETV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DRMA alert in real time by email

    NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Science Virtual Investor Forum to be held September 18th. This event is co-hosted by Zacks SCR.

    Individual investors, institutional investors, advisors, and analysts are invited to attend.

    REGISTER HERE

    It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management.

    Please schedule 1x1 meetings here

    "We are excited to highlight today's innovators from the life science sector," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. "Our Virtual Investor Conferences empower investors to connect and understand the vision driving these companies firsthand." 

    September 18th

    Eastern

    Time (ET)
    PresentationTicker(s)
    9:30 AM ETAmplia Therapeutics Limited(OTC:INNMF, ASX: ATX))
    10:00 AM ETKelyniam Global, Inc.(OTCID: KLYG)
    10:30 AM ETUnited Health Products, Inc.(OTCQB:UEEC)
    11:00 AM ETPetVivo Holdings, Inc.(OTCQX:PETV)
    11:30 AM ETDermata Therapeutics, Inc.(NASDAQ:DRMA)
    12:00 PM ETHemostemix Inc.(OTCQB:HMTXF, TSXV:HEM)
    12:30 PM ETLipella Pharmaceuticals Inc.(OTCID: LIPO)
    2:00 PM ETInmed Pharmaceuticals Inc.(NASDAQ:INM)
    2:30 PM ETAccustem Sciences Inc.(OTCQB:ACUT)
    3:00 PM ETSigyn Therapeutics Inc.(OTCQB:SIGY)
    4:00 PM ETPercheron Therapeutics Ltd.(OTCID: PERCF | ASX: PER)



    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, media@otcmarkets.com

    Virtual Investor Conferences Contact:

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    johnv@otcmarkets.com



    Primary Logo

    Get the next $DRMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRMA
    $INM
    $PETV

    CompanyDatePrice TargetRatingAnalyst
    InMed Pharmaceuticals Inc.
    $INM
    11/29/2021$6.00Buy
    HC Wainwright & Co.
    PetVivo Holdings Inc.
    $PETV
    10/12/2021$7.00Buy
    ThinkEquity
    Dermata Therapeutics Inc.
    $DRMA
    9/21/2021$14.00Buy
    Brookline Capital
    Dermata Therapeutics Inc.
    $DRMA
    9/14/2021$9.00Buy
    Maxim Group
    More analyst ratings

    $DRMA
    $INM
    $PETV
    SEC Filings

    View All

    SEC Form 425 filed by InMed Pharmaceuticals Inc.

    425 - InMed Pharmaceuticals Inc. (0001728328) (Subject)

    7/22/26 4:31:59 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by InMed Pharmaceuticals Inc.

    425 - InMed Pharmaceuticals Inc. (0001728328) (Subject)

    7/22/26 4:30:09 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InMed Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)

    7/22/26 4:28:22 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    $INM
    $PETV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on InMed Pharmaceuticals with a new price target

    HC Wainwright & Co. initiated coverage of InMed Pharmaceuticals with a rating of Buy and set a new price target of $6.00

    11/29/21 6:20:24 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ThinkEquity initiated coverage on PetVivo Holdings with a new price target

    ThinkEquity initiated coverage of PetVivo Holdings with a rating of Buy and set a new price target of $7.00

    10/12/21 11:03:37 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Brookline Capital initiated coverage on Dermata Therapeutics with a new price target

    Brookline Capital initiated coverage of Dermata Therapeutics with a rating of Buy and set a new price target of $14.00

    9/21/21 10:38:17 AM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    $INM
    $PETV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Lowenthal Garry N was granted 75,000 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    7/22/26 7:47:05 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Lai John was granted 75,000 shares (SEC Form 4)

    4 - PetVivo Holdings, Inc. (0001512922) (Issuer)

    7/22/26 7:43:25 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Large owner Adar1 Capital Management, Llc bought $1,555 worth of shares (1,000 units at $1.55) (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    7/17/26 7:29:29 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    $INM
    $PETV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline

    WALTHAM, Mass., July 22, 2026 /PRNewswire/ -- Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $200 million private placement to leading healthcare investors. The proceeds from the private placement will enable the continued development of Mentari's pipeline of targeted biologics aimed at improving outcomes for people living with migraines. Key transaction details for the private placement include:The additional $200 million private placement consisted of common stock and pre-funded warrants to purchase common stock (the "Private Place

    7/22/26 7:00:00 AM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PetVivo Holdings Announces Publication of Peer-Reviewed Clinical Study Evaluating Spryng® in Veterinary Record

    Peer-Reviewed Study Demonstrates Feasibility and Statistically Significant Improvements in Subjective Clinical Outcomes in Dogs with Stifle Osteoarthritis and Suspected Cranial Cruciate Disease Minneapolis, MN, July 14, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID: PETVW)), in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc., Cosmeta Corp and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, today announced the publication of a peer-reviewed clinical study evaluating Spryng® with OsteoCushion® Technology in the peer-reviewed journal Veterinary Record. The publication repre

    7/14/26 8:00:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo Reports Financial and Operational Results for Fiscal 2026

    MINNEAPOLIS, MN, US, June 29, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV) (OTCID: PETVW), in cooperation with its wholly-owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, reported operational results for the fourth quarter of its fiscal year ended March 31, 2026, and financial results for the full fiscal year. PetVivo will hold a conference call today at 5:00 p.m. Eastern time to discuss the results and provide a business update, followed by a question-and-answer session (see dial-in information below). Fiscal Q4 Operational Highlights

    6/29/26 5:30:00 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $DRMA
    $INM
    $PETV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Adar1 Capital Management, Llc bought $1,555 worth of shares (1,000 units at $1.55) (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    7/17/26 7:29:29 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Vivo Opportunity, Llc bought $31,846 worth of shares (20,546 units at $1.55) (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    7/16/26 9:58:22 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Vivo Opportunity, Llc bought $10,148 worth of shares (6,551 units at $1.55) (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    7/2/26 7:02:11 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    $INM
    $PETV
    Leadership Updates

    Live Leadership Updates

    View All

    Josh Ruben Joins PetVivo Holdings, Inc. Board of Directors

    MINNEAPOLIS, MN, US, Oct. 28, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTCID PETVW)), in cooperation with its wholly-owned subsidiary PetVivo Animal Health, Inc., both emerging biomedical device companies focused on the commercialization of innovative medical therapeutics for companion animals and animal athletes is pleased to announce that Josh Ruben has joined the Company's Board of Directors. "We are honored to welcome Josh Ruben to our Board of Directors," said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "Josh brings a wealth of experience in healthcare finance, capital markets, and corporate strategy, with a proven track record of executing multi-b

    10/28/25 8:00:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo and Commonwealth Partner to Advance Equine Wellness Across Thoroughbred Racing

    Minneapolis, MN, June 06, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, OTC:PETVW), an emerging biomedical device company focused on animal health, today announced a strategic collaboration with Commonwealth, the syndicated ownership group behind 2023 Kentucky Derby winner Mage, and 2022 Dubai World Cup Champion Country Grammer. The partnership centers on the clinical use and promotion of SPRYNG® with OsteoCushion® Technology, PetVivo's cutting-edge intra-articular device designed to support joint health and durability, and Precise PRP™, a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians in elite equine athletes. As part of t

    6/6/25 8:00:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo Engages Former Dechra North American President, Mike Eldred as Commercial and Operations Advisor

    PetVivo Board Appoints Eldred as Executive Director to Lead Company Product Commercialization and Operations MINNEAPOLIS, MN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV, PETVW)), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Mike Eldred as the Company's Commercialization and Operations Advisor. His appointment as an Executive Director by the Company's Board of Directors draws upon Mr. Eldred's 30 years of executive experience in animal health and the veterinary industry to ramp up its product development and sales efforts. For the past 20 years, Mr. Eldred served as President of North American Operations for Dech

    1/27/25 9:29:00 AM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    $DRMA
    $INM
    $PETV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PetVivo Holdings Inc.

    SC 13G/A - PetVivo Holdings, Inc. (0001512922) (Subject)

    11/19/24 3:38:53 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by InMed Pharmaceuticals Inc.

    SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)

    11/14/24 4:36:01 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DRMA
    $INM
    $PETV
    Financials

    Live finance-specific insights

    View All

    PetVivo Reports Financial and Operational Results for Fiscal 2026

    MINNEAPOLIS, MN, US, June 29, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV) (OTCID: PETVW), in cooperation with its wholly-owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, reported operational results for the fourth quarter of its fiscal year ended March 31, 2026, and financial results for the full fiscal year. PetVivo will hold a conference call today at 5:00 p.m. Eastern time to discuss the results and provide a business update, followed by a question-and-answer session (see dial-in information below). Fiscal Q4 Operational Highlights

    6/29/26 5:30:00 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE YEAR 2026 ENDED MARCH 31, 2026

    MINNEAPOLIS, MN, US, June 25, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV) (OTCID: PETVW), in cooperation with its wholly-owned subsidiaries, Cosmeta Corp, PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, will report financial results for the year ending March 31, 2026, on Monday, June 29, 2026 after market close. The company will host a conference call to discuss these results at 5:00 p.m. CT (6:00 p.m. ET) on the same day. Attendees of the live webcast of the conference call and related earnings release materials can register and access the webcast on PetVivo’s Investor

    6/25/26 4:04:00 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care

    PetVivo Reports Results for Third Quarter and First Nine Months of Fiscal 2026

    MINNEAPOLIS, MN, US, Feb. 17, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:PETV, OTC ID: PETVW)), and its wholly owned subsidiaries PetVivo Animal Health and PetVivo AI, a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, reported financial and operational results for the third quarter and first nine months of its fiscal year 2026 ended December 31, 2025. The company will hold a conference call today at 5:00 p.m. Eastern time to discuss the results and provide a business update, followed by a question-and-answer session (see dial-in information below). Fiscal Q3 Operational Highlights Signed an exclusive 10-ye

    2/17/26 4:30:00 PM ET
    $PETV
    Medical/Dental Instruments
    Health Care